Forest Hills Dermatology Group

1. Incyte Corporation $473,699 304 payments
2. Novartis Pharmaceuticals Corporation $395,401 4 payments
3. Regeneron Pharmaceuticals, Inc. $252,276 102 payments
4. AbbVie, Inc. $135,661 27 payments
5. Sun Pharmaceutical Industries Inc. $118,799 67 payments
6. Pfizer Inc. $72,248 25 payments
7. E.R. Squibb & Sons, L.L.C. $59,695 7 payments
8. Amgen Inc. $50,617 11 payments
9. Ucb SA $26,192 7 payments
10. Dermavant Sciences, Inc. $18,682 22 payments

1. A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of Subcutaneous Secukinumab in Subjects of Body Weight 90 KG Or Higher With Moderate to Severe Chronic Plaque Type Psoriasis $390,861 2 payments
2. A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema $290,912 59 payments
3. A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, 6 Years to 12 Years of Age, With Severe Atopic Dermatitis $60,519 8 payments
4. M15-997 $58,997 11 payments
5. An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis $58,510 11 payments
6. An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients >=6 Months to <18 Years of Age With Atopic Dermatitis $45,689 37 payments
7. A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $43,698 87 payments
8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis $43,632 22 payments
9. Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis $42,468 30 payments
10. A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) $38,122 7 payments

1. Professional salary support $37,532 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.